A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Inclusion criteria:

1. Understands the study procedures in the informed consent form (ICF), and be willingand able to comply with the protocol.
2. Healthy, adult, male or female of non-childbearing potential, 18-55 years of age,inclusive, at the screening visit.
3. Male participants must follow protocol specified contraception guidance.
4. Continuous non-smoker who has not used nicotine- and tobacco-containing products forat least 3 months prior to the first dosing based on participant self-reporting.
5. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m^2 at the screening visit.
6. Medically healthy with no clinically significant medical history, physicalexamination, laboratory profiles, vital signs, and electrocardiograms (ECGs), asdeemed by the Investigator or designee, including the following:

• Seated blood pressure (BP) is ≥ 90/40 millimeter of mercury (mmHg) and ≤ 140/90mmHg at the screening visit.
• Seated pulse rate is ≥ 40 beats per minute (bpm) and ≤ 99 bpm at the screeningvisit.
• Part 1 only: QTcF interval is ≤ 450 msec (males and females) and has ECG findingsconsidered normal or not clinically significant by the Investigator or designeeat the screening visit.
• Part 2 and 3: ECG findings considered normal or not clinically significant by theInvestigator or designee at the screening visit.
• Estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73m^2 at the screeningvisit.
• Liver function tests including Alanine aminotransferase (ALT), Aspartateaminotransferase (AST), Alkaline phosphatase (ALP), and total bilirubin ≤ upperlimit of normal (ULN) at the screening visit and at check-in.
• No clinically significant hypokalemia or hypomagnesemia at the screening visit.

Exclusion criteria:

1. Is mentally or legally incapacitated or has significant emotional problems at the timeof the screening visit or expected during the conduct of the study.
2. History or presence of clinically significant medical or psychiatric condition ordisease in the opinion of the Investigator or designee.
3. History of any illness that, in the opinion of the Investigator or designee, mightconfound the results of the study or poses an additional risk to the participant bytheir participation in the study.
4. Has a history of any of the following:

• Active infection or febrile illness within 7 days prior to first dosing, asassessed by the Investigator or designee.
• Symptoms suggestive of systemic or invasive infection requiring hospitalizationor treatment within 8 weeks prior to first dosing.
• Chronic or recurrent bacterial disease, including but not limited to chronicpyelonephritis or cystitis, chronic bronchitis/pneumonitis, osteomyelitis, orchronic skin ulcerations/infections or fungal infections (except superficialnailbed mycosis).
• An infected joint prosthesis unless that prosthesis has been removed or replacedgreater than 60 days prior to first dosing.
• Opportunistic infections (eg, Pneumocystis jirovecii pneumonia, histoplasmosis,coccidiomycosis).
• Cancer or lymphoproliferative disease within 5 years prior to first dosing, withthe exception of successfully treated nonmetastatic cutaneous squamous cell orbasal cell carcinoma and/or localized carcinoma in situ of the cervix is notexclusionary.
• Known or suspected condition/illness that is consistent with compromisedimmunity, including but not limited to any identified congenital or acquiredimmunodeficiency; splenectomy.
• Liver or other solid organ transplant.

5. Has history or presence of alcoholism and/or drug abuse within the past 2 years priorto first dosing, as determined by the Investigator or designee.
6. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,including macrolide antibiotics (Part 1 only; eg, erythromycin) or anti-seizure agents (Part 2 only; eg, phenytoin) or anti-viral drugs (Part 3 only; eg, efavirenz).
7. Part 2 and Part 3 only: Any positive responses on the Columbia-Suicide Severity RatingScale (C-SSRS) or has a risk of suicide according to the Investigator's or designeejudgment based on the assessment of the C-SSRS at the screening visit or check-in orhas made a suicide attempt within 12 months before the first dosing.
8. Part 2 only: History of seizure (excluding simple febrile seizure), epilepsy, severehead injury, multiple sclerosis, or other known neurological conditions which theInvestigator or designee considers to be clinically significant.
9. Part 2 only: Participant is known to be a CYP2C9 and/or CYP2C19 poor metabolizer basedon genotyping prior to screening or is determined to be a CYP2C9 and/or CYP2C19 poormetabolizer at the screening visit.
10. History or presence of ventricular dysfunction or risk factors for Torsades de Pointes (eg, heart failure, cardiomyopathy, family history of Long QT Syndrome).
11. Female participant of childbearing potential.
12. Female participant with a positive pregnancy test at the screening visit or atcheck-in or who is lactating.
13. Positive urine drug or alcohol results at the screening visit or check-in.
14. Unable to refrain from or anticipates the use of:

• Any drugs, including prescription and non-prescription medications, herbalremedies, or vitamin supplements beginning 14 days prior to the first dosing.
• Any drugs known to be moderate or strong inducers of CYP3A4 enzymes and/orP-glycoprotein (P-gp), including St. John's Wort, for 28 days prior to the firstdosing. Appropriate sources (eg, Flockhart Table™) including the product labelfor erythromycin (Erythromycin Tablets USP 2018), phenytoin (DILANTIN (extendedphenytoin sodium capsules) 2022), and efavirenz (SUSTIVA (efavirenz) capsules andtablets 2019) will be consulted to confirm lack of pharmacokinetic (PK)/pharmacodynamic interaction with the study drugs.

15. Has been on a diet incompatible with the on study diet, in the opinion of theInvestigator or designee, within the 30 days prior to first dosing and throughout thestudy.
16. Has made a donation of blood or had significant blood loss within 56 days prior tofirst dosing.
17. Has made a plasma donation within 7 days prior to first dosing.
18. Participated in another clinical study within 30 days prior to first dosing. The 30day window will be derived from the date of the last dosing in the previous study toDay 1 of Period 1 of the current study.
19. Herpes infections:

• Participant has active herpes virus infection, including herpes zoster or herpessimplex 1 and 2 (demonstrated on physical examination and/or medical history) atscreening or Day 1 of Period 1.
• Participant has history of serious herpetic infection that includes any episodeof disseminated disease, multidermatomal herpes simplex virus, herpesencephalitis, ophthalmic herpes, or recurrent herpes zoster (defined as 2episodes within 2 years).

20. Positive results for non-herpetic viral diseases at the screening visit:

• Hepatitis C virus (HCV) antibody and a positive confirmatory test result for HCVribonucleic acid (RNA) (nucleic acid test or polymerase chain reaction [PCR]);
• Hepatitis B surface antigen (HBsAg)+, hepatitis B virus deoxyribonucleic acid (DNA), or HBcAb+ with positive hepatitis B virus DNA;
• Human immunodeficiency virus (HIV).

21. Positive results for tuberculosis (TB) at the screening visit or has the following:

• Has history of active TB infection, regardless of treatment status.
• Has signs or symptoms of active TB (including but not limited to chronic fever,chronic productive cough, night sweats, or weight loss) as judged by theinvestigator or designee.
• Has evidence of latent tuberculosis infection (LTBI) as evidenced by a positiveQFT result OR 2 indeterminant Quantiferon TB Gold (QFT) results and does not havedocumentation of appropriate LTBI prophylaxis. Participant remains eligible if heor she can provide documentation of prior and complete treatment for LTBI (appropriate in duration and type per current local country guidelines).
• Has had any imaging study during or 6 months prior to screening, including x-ray,chest computed tomography, magnetic resonance imaging, or other chest imagingsuggesting evidence of current active or a history of active TB.

22. Part 3 only: History of amphetamine and methylphenidate use; history or presence ofsleeping disorders or sleeping irregularities, or any significant cardiac abnormalityin the opinion of the Investigator or designee.
23. Part 2 and Part 3 only: History or presence of Stevens-Johnson Syndrome and/orseizures.